Patient baseline characteristics (intention-to-treat population)
| Characteristics | Esomeprazole | Placebo (n=805) | |
| 40 mg once daily (n=817) | 20 mg once daily (n=804) | ||
| Men | 437 (53.5) | 429 (53.4) | 403 (50.1) |
| Age | |||
| Mean, years (range) | 67.7 (21–87) | 67.7 (24–89) | 67.4 (24–94) |
| >70 years | 299 (36.6) | 286 (35.6) | 282 (35.0) |
| Ethnicity | |||
| White | 669 (81.9) | 651 (81.0) | 661 (82.1) |
| Black/African-American | 30 (3.7) | 31 (3.9) | 23 (2.9) |
| Asian | 76 (9.3) | 77 (9.6) | 82 (10.2) |
| Other* | 42 (5.1) | 45 (5.6) | 39 (4.8) |
| Current smoker | 77 (9.4) | 73 (9.1) | 73 (9.1) |
| Helicobacter pylori status | |||
| H pylori negative | 606 (74.2) | 605 (75.2) | 574 (71.3) |
| H pylori positive | 159 (19.5) | 149 (18.5) | 171 (21.2) |
| Missing/indeterminate status | 52 (6.4) | 50 (6.2) | 60 (7.4) |
| History of gastric ulcer | 108 (13.2) | 100 (12.4) | 89 (11.1) |
| History of duodenal ulcer | 111 (13.6) | 121 (15.0) | 133 (16.5) |
| History of erosive (reflux) oesophagitis | 56 (6.9) | 63 (7.8) | 61 (7.6) |
| Past PCI | 112 (13.7) | 103 (12.8) | 102 (12.7) |
| Past CABG | 85 (10.4) | 85 (10.6) | 81 (10.1) |
| Low-dose ASA use | |||
| Primary prevention | 363 (44.4) | 368 (45.8) | 386 (48.0) |
| Secondary prevention | 435 (53.2) | 421 (52.4) | 401 (49.8) |
| Mean dose, mg (range) | 112.1 (75–325) | 109.2 (50–325) | 107.7 (75–325) |
| 101–325 mg/day | 178 (21.8) | 171 (21.3) | 161 (20.0) |
| >4 weeks' duration | 713 (87.3) | 684 (85.1) | 700 (87.0) |
Variables are n (%) unless otherwise stated.
↵* Including native Hawaiian/Pacific Islander, American Indian/Alaska native, Hispanic, Middle Eastern, Caribbean Island, Black/South African or mixed ethnicity.
ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.